reports
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million,...
Harrow Reaffirms 2025 Full-Year Revenue Guidance of $270–$280 Million, Marking Another Year of Strong Growth Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding OneHarrow Initiative is Launched to Unify Branding under Harrow Patrick W. Sullivan Promoted to Serve as Harrow’s Chief Commercial Officer MELT-300 and MELT-210 Programs on Track for New Drug Application Filings Harrow’s ImprimisRx Settles Pending Regulatory Matters with...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Fol...
Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review processCompany expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today provided a regulatory update regarding its Biologics License Application (BLA) for Deramiocel, the Company’s...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host We...
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy – Webinar to be held Wednesday, December 17, 2025, at 1:00 p.m. ET – SAN DIEGO, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced that Parent Project Muscular Dystrophy (PPMD) will host a community webinar to share and discuss positive topline results from Capricor’s Phase 3 HOPE-3 trial evaluating Deramiocel, the Company’s...
Capricor Therapeutics Announces Pricing of $150 Million Public Offerin...
Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the pricing of its underwritten public offering of 6,000,000 shares of common stock at a public offering price of $25.00 per share. Capricor also granted the underwriters a 30-day option to purchase up to an additional 900,000 shares of its common stock at the public offering price, less the underwriting discounts...
Capricor Therapeutics Announces Proposed Public Offering of Common Sto...
Capricor Therapeutics Announces Proposed Public Offering of Common Stock SAN DIEGO, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced the commencement of a proposed underwritten public offering of shares of its common stock. In addition, Capricor intends to grant the underwriters a 30-day option to purchase an additional number of shares of common stock equal to 15% of the aggregate number of shares of its common stock sold in the public offering. The proposed...
Capricor Therapeutics Announces Positive Topline Results from Pivotal ...
Capricor Therapeutics Announces Positive Topline Results from Pivotal Phase 3 HOPE-3 Study of Deramiocel in Duchenne Muscular Dystrophy Pivotal Phase 3 randomized, double-blind, placebo-controlled study (n=106) met the primary endpoint (PUL v2.0) and the key secondary cardiac endpoint (LVEF), both achieving statistical significance (p=0.03 and p=0.04, respectively)Statistical significance was achieved in all type 1 error controlled secondary endpoints Results demonstrate clinically meaningful and statistically significant skeletal and cardiac benefits, supporting Deramiocel as a potential f...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
TPC TUTOR PERINI CORPORATION
SLGN SILGAN HOLDINGS INC.
RPD RAPID7 INC.
OPK OPKO HEALTH INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
NCLH NORWEGIAN CRUISE LINE HOLDINGS LTD.
MTDR MATADOR RESOURCES COMPANY
GBCI GLACIER BANCORP INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FOXF FOX FACTORY HOLDING CORP.
EIG EMPLOYERS HOLDINGS INC.
ARCC ARES CAPITAL CORPORATION
RLMD RELMADA THERAPEUTICS
TREX TREX COMPANY INC.
VVV VALVOLINE INC.
KREF KKR REAL ESTATE FINANCE TRUST
HLNE HAMILTON LANE INCORPORATED CLASS A
SONO SONOS
VRCA VERRICA PHARMACEUTICALS
AMCR AMCOR PLC
AVTR AVANTOR
TSLX INC.
VLA SIXTH STREET SPECIALTY LENDING
MRVI INC.
FRSH ARBOR METALS
SG MARAVAI LIFESCIENCES HOLDINGS
TBBK FRESHWORKS INC.
QDEL SWEETGREEN INC
BHVN THE BANCORP
WEST INC.
SMRT QUIDEL CORP
CRVO BIOHAVEN LTD
NCDL WESTROCK COFFEE COMPANY LLC
GAM SMARTRENT INC
STRZ CERVOMED INC
GMRE NUVEEN CHURCHILL DIRECT LENDING CORP
OESX GENERAL DE ALQUILER DE MAQUINARIA
STARZ ENTERTAINMENT CORP
GLOBAL MEDICAL REIT INC.
ORION ENERGY SYSTEMS INC
- Jonathan Moreland
- Jonathan Moreland
RPD RAPID7 INC.
LOB LIVE OAK BANCSHARES
JACK JACK IN THE BOX INC.
HFWA HERITAGE FINANCIAL CORPORATION
EGBN EAGLE BANCORP INC.
DIN DINE BRANDS GLOBAL INC.
CLX CLOROX COMPANY
KYN KAYNE ANDERSON MLP INVESTMENT CO.
VVV VALVOLINE INC.
INSE INSPIRED ENTERTAINMENT
MLP MAUI LAND & PINEAPPLE CO. INC.
USPH U.S. PHYSICAL THERAPY
AEYE INC.
UTZ AUDIOEYE INC
AUID UTZ BRANDS INC (A)
NEXT IPSIDY INC.
BBWI NEXT CAPITAL
EVLV BATH & BODY WORKS INC
CWGL EVOLV TECHNOLOGIES HLDGS INC
QDEL CRIMSON WINE GROUP
WEST LTD
PROP QUIDEL CORP
SPRU WESTROCK COFFEE COMPANY LLC
GF PRAIRIE OPERATING CO.
NOV SPRUCE POWER HOLDING CORP
THE NEW GERMANY FUND
INC.
NATIONAL OILWELL VARCO
INC. 
Capricor Therapeutics Presents New Data Demonstrating a Scalable Frame...
Capricor Therapeutics Presents New Data Demonstrating a Scalable Framework for Loading Therapeutic Oligonucleotides into Exosomes at AAEV 2025 --Findings support the versatility of Capricor’s exosome technology, enabling efficient and scalable loading of siRNAs and PMOs to support future clinical development-- SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- ., (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics, today announced new data describing a scalable framework for loading therapeutic small interfering RNAs (siRNA) and phosphorodiamid...
Harrow to Present at Two Investor Conferences in December
Harrow to Present at Two Investor Conferences in December NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5th Annual Ophthalmology Day (Virtual)Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37th Annual Healthcare Conference (New York, NY)Format: Fireside chatDate/Time: Tuesday, December 2, 2025, at 3:00 PM EST The fireside chat at Pi...
- Jonathan Moreland
STAA STAAR SURGICAL CO.
MYE MYERS INDUSTRIES INC.
KVHI KVH INDUSTRIES INC.
GOGO GOGO INC.
GLP GLOBAL PARTNERS LP
FAST FASTENAL COMPANY
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
CNS COHEN & STEERS INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
AP AMPCO-PITTSBURGH
KYN KAYNE ANDERSON MLP INVESTMENT CO.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
SONO SONOS
AEYE AUDIOEYE INC
AVTR AVANTOR
TELA INC.
UTZ TELA BIO
ACVA UTZ BRANDS INC (A)
NEXT ACV AUCTIONS INC.
EVLV NEXT CAPITAL
BHVN EVOLV TECHNOLOGIES HLDGS INC
VANI BIOHAVEN LTD
WEST VIVANI MEDICAL INC
SMRT WESTROCK COFFEE COMPANY LLC
GTE SMARTRENT INC
ET GRAN TIERRA ENERGY INC.
MNR ENERGY TRANSFER LP
CRVO MACH NATURAL RESOURCES LP
NCDL CERVOMED INC
SPRU NUVEEN CHURCHILL DIRECT LENDING CORP
MXF SPRUCE POWER HOLDING CORP
GF THE MEXICO FUND
HYMC INC.
BATRK THE NEW GERMANY FUND
GMRE INC.
ANNX HYCROFT MINING HOLDING CORPORATION
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
ANNEXIN PHARMACEUTICALS AB (PUBL)
- Jonathan Moreland
DEI DOUGLAS EMMETT INC
SPG SIMON PROPERTY GROUP INC.
OPK OPKO HEALTH INC.
MYE MYERS INDUSTRIES INC.
GOGO GOGO INC.
CPSI COMPUTER PROGRAMS & SYSTEMS INC.
AP AMPCO-PITTSBURGH
INBK FIRST INTERNET BANCORP
PRKR PARKERVISION INC.
MSEX MIDDLESEX WATER CO.
SONO SONOS
TMDX TRANSMEDICS GROUP
NML NEUBERGER BERMAN MLP INCOME FUND INC.
VLA ARBOR METALS
ACVA ACV AUCTIONS INC.
NRDY NERDY INC.
BHVN BIOHAVEN LTD
MNR MACH NATURAL RESOURCES LP
MXF THE MEXICO FUND
GF INC.
RMI THE NEW GERMANY FUND
LPSN INC.
RIVERNORTH OPPOR MUN INC FD INC
LIVEPERSON INC.
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals
Harrow Announces Closing of Acquisition of Melt Pharmaceuticals NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and in-office settings. Melt’s product candidates, MELT-210, MELT-300, and MELT-400, are based on the proprietary Zydis® ODT (oral dissolvi...
- Jonathan Moreland
TPVG TRIPLEPOINT VENTURE GROWTH BDC CORP
KVHI KVH INDUSTRIES INC.
GLP GLOBAL PARTNERS LP
FOXF FOX FACTORY HOLDING CORP.
FLDM FLUIDIGM
ALG ALAMO GROUP INC.
GAM GENERAL AMERICAN INVESTORS CO. INC.
MSM MSC INDUSTRIAL DIRECT CO. INC. CLASS A
TREX TREX COMPANY INC.
ICHR ICHOR HOLDINGS LTD.
CELH CELSIUS HOLDINGS INC.
HFFG HF FOODS GROUP INC
AVTR AVANTOR
PGNY INC.
TELA PROGYNY
SMCI TELA BIO
MRVI SUPER MICRO COMPUTER
BLND INC.
BHVN MARAVAI LIFESCIENCES HOLDINGS
DRCT ETRACS DJ-UBS COMMODITY INDEX 2-4-6 BLEND
VANI BIOHAVEN LTD
GTE DIRECT DIGITAL HLDGS INC
GT VIVANI MEDICAL INC
CRVO GRAN TIERRA ENERGY INC.
NCDL GOODYEAR TIRE & RUBBER CO.
NEXT CERVOMED INC
CATX NUVEEN CHURCHILL DIRECT LENDING CORP
RMI NEXTSOURCE MATERIALS INC.
BATRK PERSPECTIVE THERAPEUTICS
GMRE INC.
RIVERNORTH OPPOR MUN INC FD INC
LIBERTY MEDIA CORP
GLOBAL MEDICAL REIT INC.
Harrow Announces Third Quarter 2025 Financial Results
Harrow Announces Third Quarter 2025 Financial Results Third-Quarter 2025 and Recent Selected Highlights: Total revenues of $71.6 million, a 45% increase over $49.3 million recorded in the prior-year periodGAAP net income of $1.0 millionAdjusted EBITDA of $22.7 millionCash and cash equivalents of $74.3 million as of September 30, 2025 NASHVILLE, Tenn., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, announced results for the third quarter ended September 30, 2025. The Company also posted its thi...
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and...
Capricor Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Topline results from pivotal HOPE-3 Phase 3 study (n=105) of Deramiocel for the treatment of Duchenne muscular dystrophy expected in the coming weeks (Q4 2025)Pending the results of the topline data from the HOPE-3 study, the Company expects to resubmit its BLA, leveraging the data in support of its application for approvalCommercial launch preparations underway to support potential approval and market introduction of Deramiocel in 2026NIAID-sponsored Phase 1 clinical trial underway with Stealth...
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines De...
Capricor Therapeutics Publishes Peer-Reviewed Study in Biomedicines Describing the Mechanism of Action and Potency Assay for its Investigational Cell Therapy, Deramiocel –Publication highlights Deramiocel’s anti-fibrotic activity and describes a validated potency assay supporting quality control and product consistency in late-stage development– SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- . (NASDAQ: CAPR), a biotechnology company developing cell and exosome-based therapies for rare diseases, today announced the publication in Biomedicines, an international peer-reviewed journal, descri...
Capricor Therapeutics to Present Third Quarter 2025 Financial Results ...
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 Company to Host Conference Call on November 10, 2025, at 4:30 p.m. ET SAN DIEGO, Oct. 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the third quarter ended September 30, 2025, after the market close on Monday, November 10, 2025. Management will then host a webcast and conference call at 4:30 p....
Harrow To Report Third Quarter 2025 Financial Results After Market Clo...
Harrow To Report Third Quarter 2025 Financial Results After Market Close on November 10, 2025 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on November 11, 2025 NASHVILLE, Tenn., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the third quarter ended September 30, 2025, on Monday, November 10, 2025, after the market close. The Company will also post its third quarter Letter to Stockholders to the “Investors”...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.